Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • « Prev · Page [96]
NCT ID: NCT00251849 Active, not recruiting - Clinical trials for Intermittent Claudication

PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine whether rifalazil can significantly increase peak walking time (PWT) in patients with peripheral arterial disease (PAD).

NCT ID: NCT00099437 Active, not recruiting - Breast Cancer Clinical Trials

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

CONFIRM
Start date: February 13, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.

NCT ID: NCT00066703 Active, not recruiting - Breast Cancer Clinical Trials

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

TEXT
Start date: November 3, 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer. PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.

NCT ID: NCT00052156 Active, not recruiting - Malignant Melanoma Clinical Trials

Vaccine Therapy for Patients With Stage IV Melanoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

NCT ID: NCT00052130 Active, not recruiting - Malignant Melanoma Clinical Trials

Vaccine Therapy for Patients With Stage III Melanoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

NCT ID: NCT00045032 Active, not recruiting - Breast Cancer Clinical Trials

Trastuzumab in Treating Women With Primary Breast Cancer

Start date: December 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether trastuzumab is effective in treating primary breast cancer in women who have completed adjuvant chemotherapy. PURPOSE: This randomized phase III trial is studying two different regimens of trastuzumab and observation only to compare how well they work in treating women with breast cancer.

NCT ID: NCT00022516 Active, not recruiting - Breast Cancer Clinical Trials

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

22-00
Start date: November 2000
Phase: Phase 3
Study type: Interventional

This randomized, phase III trial was designed to test the efficacy of a low-dose chemotherapy-maintenance regimen, hypothesized to have anti-angiogenic activity, administered following standard chemotherapy in patients with early breast cancer whose tumors are hormone receptor negative.